Cancer Immunotherapy and Biomarkers

Cancer immunotherapy works by redirecting the body's own immune system to recognize and destroy tumor cells, most notably through drugs that block inhibitory proteins like PD-1 and PD-L1, which tumors exploit to evade immune attack. Whether a patient responds to these treatments depends on a complex interplay of factors within the tumor microenvironment, including the mutational burden of the cancer, the presence of neoantigens that immune cells can recognize, and the degree to which T-cells have become exhausted and functionally impaired. Identifying reliable biomarkers that predict who will benefit from checkpoint blockade—and who risks serious immune-related side effects—remains one of the field's central challenges. Researchers are also working to understand how tumors adapt and escape immune pressure over time, a process called immunoediting, and how combining immunotherapy with other treatments might overcome that resistance.

Works

141,254

Total citations

2,780,611

Keywords

Immune Checkpoint BlockadePD-1 and PD-L1Tumor MicroenvironmentTumor Mutational BurdenImmune-related Adverse EventsT-cell Exhaustion